Invivyd is a biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and/or treatment of viral infectious disease. Co. is obtaining regulatory authorization or approval for its lead product candidate, VYD222, for the prevention and/or treatment of SARS-CoV-2 (COVID-19). VYD222 is an engineered version of adintrevimab, Co.'s investigational monoclonal antibody. Co. is developing a pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. The IVVD stock yearly return is shown above.
The yearly return on the IVVD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IVVD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|